Antoine Hollebecque

Antoine Hollebecque

UNVERIFIED PROFILE

Are you Antoine Hollebecque?   Register this Author

Register author
Antoine Hollebecque

Antoine Hollebecque

Publications by authors named "Antoine Hollebecque"

Are you Antoine Hollebecque?   Register this Author

95Publications

3727Reads

47Profile Views

Facts and new hopes on selective FGFR inhibitors in solid tumors.

Clin Cancer Res 2019 Oct 4. Epub 2019 Oct 4.

INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-2035DOI Listing
October 2019

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lancet Gastroenterol Hepatol 2019 Sep 9;4(9):711-720. Epub 2019 Jul 9.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30189-XDOI Listing
September 2019

Molecular targeted therapy of -mutant colorectal cancer.

Ther Adv Med Oncol 2019 18;11:1758835919856494. Epub 2019 Jun 18.

Département de Chirurgie Viscérale, Gustave Roussy Cancer Campus Grand Paris, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919856494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582307PMC
June 2019

Systemic treatment of pancreatic cancer revisited.

Semin Oncol 2019 Feb 27;46(1):28-38. Epub 2018 Dec 27.

Département d'oncologie médicale, Institut de Cancérologie de Lorraine, Université de Lorraine, Nancy, France.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00937754183026
Publisher Site
http://dx.doi.org/10.1053/j.seminoncol.2018.12.003DOI Listing
February 2019

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Eur J Cancer 2018 11 14;103:108-119. Epub 2018 Sep 14.

Department of Interventional Radiology, Gustave Roussy, Villejuif, France; Faculté de Médecine, Kremlin-Bicêtre, Université Paris Sud, France; Laboratory of Translational Research in Immunology - LRTI, INSERM U1015, Gustave Roussy, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.08.003DOI Listing
November 2018

BRAF Inhibition in BRAF-Mutant Gliomas: Results From the VE-BASKET Study.

J Clin Oncol 2018 Oct 23:JCO2018789990. Epub 2018 Oct 23.

Thomas Kaley, Lisa M. DeAngelis, Jose Baselga, and David M. Hyman, Memorial Sloan Kettering Cancer Center; Thomas Kaley, Lisa M. DeAngelis, Jose Baselga, and David M. Hyman, Weill Cornell Medical College, New York; Igor Puzanov, Roswell Park Cancer Institute, Buffalo, NY; Mehdi Touat and Antoine Hollebecque, Institut Gustave Roussy, Villejuif; Franck Bielle, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, Paris; Florence Joly, Centre François Baclesse, Caen; Jean-Yves Blay, Centre Léon Bérard, Lyon, France; Vivek Subbiah, MD Anderson Cancer Center, Houston, TX; Jordi Rodon, Vall d'Hebron University Hospital, Barcelona, Spain; A. Craig Lockhart, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Vicki Keedy, Vanderbilt University Medical Center, Nashville, TN; Ralf-Dieter Hofheinz, Universitätsmedizin Mannheim, Mannheim; Jurgen Wolf, Universitätsklinikum Köln, Cologne, Germany; Ian Chau, The Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Noopur S. Raje, Massachusetts General Hospital, Boston, MA; Martina Makrutzki, F Hoffmann-La Roche, Basel, Switzerland; Todd Riehl, Genentech, South San Francisco, CA; and Bethany Pitcher, F Hoffmann-La Roche, Mississauga, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9990
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286161PMC
October 2018

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Lancet Oncol 2018 09 14;19(9):1180-1191. Epub 2018 Aug 14.

Gustave Roussy-CentraleSupélec-Therapanacea Centre of Artificial Intelligence in Radiation Therapy and Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Radiomics Team, Molecular Radiotherapy INSERM U1030, Paris-Sud University, Gustave Roussy Cancer Campus, and University of Paris-Saclay, Villejuif, France; Department of Drug Development, Gustave Roussy Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30413-3DOI Listing
September 2018

Vemurafenib and cobimetinib overcome resistance to vemurafenib in -mutant ganglioglioma.

Neurology 2018 09 17;91(11):523-525. Epub 2018 Aug 17.

From Sorbonne Université (M.T., A.I., M.S., A.L.D.S.), Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neurologie 2-Mazarin, Paris, France; Department of Oncologic Pathology (M.T., K.L.L.), Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; Department of Neuroradiology (J.G., S.C.A.), Pharmacy Department (K.S.), and Departments of Neurosurgery (S.A.), Pathology (C.V.), and Neurology (A.L.D.S.), Hôpital Foch, Suresnes; Department of Radiology (J.S.), Fondation Ophtalmologique Adolphe de Rothschild, Paris; Département de Génétique (G.P., A.-P.G.-R., P.L.-P.), and Service de Biochimie, UF de Pharmacogénétique et Oncologie Moléculaire (H.B.), Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris; INSERM (G.P., H.B., P.L.-P.), UMR S 1147, Paris; Drug Development Department (A.H.), Gustave Roussy, Université Paris-Saclay, Villejuif; INSERM (A.-P.G.-R.), UMR970, Paris-Cardiovascular Research Center, Equipe Labellisée par la Ligue contre le Cancer, Paris; and Université Paris Descartes (H.B., A.-P.G.-R., P.L.-P.), Sorbonne Paris Cité, Faculté de Médecine, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006171DOI Listing
September 2018

Multilayer global longitudinal strain in patients with cancer: A comparison of two vendors.

Arch Cardiovasc Dis 2018 Apr;111(4):285-296

Service de cardiologie, hôpital Saint-Antoine, AP-HP, université Pierre-et-Marie-Curie, Paris-Sorbonne, Paris VI, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acvd.2017.11.003DOI Listing
April 2018

Are phase I trials safe for older patients?

J Geriatr Oncol 2018 03 8;9(2):87-92. Epub 2017 Sep 8.

Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif Cedex F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.08.012DOI Listing
March 2018

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study.

Clin Colorectal Cancer 2018 03 19;17(1):e99-e107. Epub 2017 Oct 19.

Service d'oncologie médicale, Hôpital Claude Huriez, University Hospital, Lille, France; Université Lille Nord de France, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2017.10.001DOI Listing
March 2018

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Eur J Cancer 2018 03 3;92:1-10. Epub 2018 Feb 3.

Drug Development Department, Gustave Roussy, Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France; Gustave Roussy Department of Medical Oncology, Faculté de Medicine Paris-Sud XI, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.12.020DOI Listing
March 2018

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Eur J Cancer 2017 10 18;84:202-211. Epub 2017 Aug 18.

Drug Development Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France; Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.033DOI Listing
October 2017

First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours.

Eur J Cancer 2017 08;81:142-150

Drug Development Department DITEP, Institut Gustave Roussy, 94805, Villejuif, France; Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Orsay, 91405, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.007DOI Listing
August 2017

Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?

Eur J Cancer 2017 08 17;81:161-173. Epub 2017 Jun 17.

Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Villejuif, F-94805, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.05.006DOI Listing
August 2017

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Cancer Chemother Pharmacol 2017 Jun 19;79(6):1257-1265. Epub 2017 Apr 19.

Drug Development Department (DITEP), Gustave Roussy Cancer Centre, Université Paris-Saclay, 114 Rue Eduard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3303-zDOI Listing
June 2017

Patient-reported tolerability of adverse events in phase 1 trials.

ESMO Open 2017 23;2(2):e000148. Epub 2017 Jun 23.

Drug Development department (DITEP), Gustave Roussy Cancer Campus, Paris-Saclay University, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519806PMC
June 2017

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Clin Cancer Res 2017 04 8;23(8):1920-1928. Epub 2016 Nov 8.

Département d'Innovation Thérapeutique et des Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/early/2016/11/
Web Search
http://dx.doi.org/10.1158/1078-0432.CCR-16-1741DOI Listing
April 2017

Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.

Semin Oncol 2017 04 2;44(2):114-128. Epub 2017 Aug 2.

Département de Médecine Oncologique, Gustave Roussy, Université Paris-Saclay, Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2017.07.004DOI Listing
April 2017

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.

Anticancer Drugs 2017 03;28(3):341-349

aGustave Roussy Cancer Centre, Paris-Saclay University, Drug Development Department (DITEP), Villejuif bHospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Benite Cedex cHematology and Cellular Therapy Department, CIC INSERM 1415, University Hospital Centre, Tours, France dCancer Institute of New Jersey, New Brunswick, New Jersey, USA ePharmaMar, S.A., Colmenar Viejo, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000457DOI Listing
March 2017

Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials.

Invest New Drugs 2017 02 25;35(1):79-86. Epub 2016 Oct 25.

Clinical Pharmacology, Henri Mondor Teaching Hospital, 51 avenue du Maréchal de Lattre de Tassigny, Assistance Publique - Hôpitaux de Paris, 94000, Créteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-016-0402-3DOI Listing
February 2017

[Early detection of cancer therapeutics-related cardiac dysfunction].

Bull Cancer 2016 Jul-Aug;103(7-8):667-73. Epub 2016 Jul 12.

AP-HP, université Pierre-et-Marie-Curie, hôpitaux de l'Est parisien (Saint-Antoine-Tenon), service de cardiologie, Paris-Sorbonne, 184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France; Unité INSERM 856 «Thrombose, athérothrombose et pharmacologie appliquée», 75013 Paris, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2016.05.004DOI Listing
January 2017

Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.

Clin Cancer Res 2016 06 12;22(12):2960-8. Epub 2016 Jan 12.

Laboratoire de Recherche Translationnelle et Centre de RessourcesBiologiques, AMMICA, INSERM US23/CNRS UMS3655, Gustave Roussy, Villejuif, France. INSERM U981, Gustave Roussy, Villejuif, France. Département de Biologie et Pathologie Médicales, Gustave Roussy, Villejuif, France. Faculté de Pharmacie, Université Paris Sud, Châtenay-Malabry, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2470DOI Listing
June 2016

Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?

Hepat Oncol 2016 Apr 23;3(2):109-118. Epub 2016 Mar 23.

Department of Image Guided Therapy, Gustave Roussy-Cancer Campus, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/hep-2015-0001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095432PMC
April 2016

Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.

Cancer Biomark 2015 ;15(2):151-6

Thoracic Group, INSERM U981, Gustave Roussy, Villejuif, France Department of Medical Oncology, Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/CBM-140448DOI Listing
February 2016

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.

Clin Cancer Res 2015 Dec 17;21(23):5235-44. Epub 2015 Jul 17.

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0180DOI Listing
December 2015

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

N Engl J Med 2015 Aug;373(8):726-36

From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut Bergonié Cancer Center, Bordeaux (A.I.) - all in France; University Hospital of Cologne, Cologne (J.W.), Universitätsmedizin Mannheim, Mannheim (R.-D.H.), West German Cancer Center, University Hospital Essen, Essen (M.S.), and German Cancer Consortium, Heidelberg (M.S.) - all in Germany; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona (M.E.E.-F., J.T.), and Hospital Universitario Madrid Sanchinarro, Madrid (M.H.) - both in Spain; and F. Hoffmann-La Roche, Basel, Switzerland (S.F.L., M.M., F.S., M.L.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1502309DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971773PMC
August 2015

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

Eur J Cancer 2015 Feb 2;51(3):327-39. Epub 2015 Jan 2.

Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.12.005DOI Listing
February 2015

[Communication in the context of phase I clinical trials in oncology: implementation and evaluation of training programs].

Bull Cancer 2015 Feb 15;102(2):174-81. Epub 2015 Jan 15.

Institut Gustave-Roussy, département interdisciplinaire de soins de support aux patients en oncohématologie, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2014.12.013DOI Listing
February 2015

Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.

Medicine (Baltimore) 2014 Nov;93(24):333-9

From the Department of Nephrology (HI, VG, AB) and Pathology (PR), Pitié Salpêtrière Hospital, Paris; Department of Medical Oncology (BE, LD) and Gynecology (CL, PP), and Drug Development Department (DITEP) (RB, AH, JCS), Gustave Roussy Institute, VilleJuif; and Department of Nephrology (DS), UMRS 955 (DS), Henri Mondor Hospital, Creteil, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000000207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602430PMC
November 2014

Dysphonia induced by anti-angiogenic compounds.

Invest New Drugs 2014 Aug 18;32(4):774-82. Epub 2013 Dec 18.

DITEP (Département d'Innovations Thérapeutiques et d'Essais Précoces) Département de Médicine Oncologique, Gustave Roussy, Villejuif, France,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-013-0049-2
Publisher Site
http://dx.doi.org/10.1007/s10637-013-0049-2DOI Listing
August 2014

Pharmacokinetics of pazopanib administered in combination with bevacizumab.

Cancer Chemother Pharmacol 2014 Jun 6;73(6):1189-96. Epub 2014 Apr 6.

EA4553 Institut Claudius-Regaud, Université de Toulouse, 20, rue du Pont-Saint-Pierre, 31052, Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-014-2455-3DOI Listing
June 2014

Implementing precision medicine initiatives in the clinic: a new paradigm in drug development.

Curr Opin Oncol 2014 May;26(3):340-6

aDrug Development Department (DITEP: Département d'Innovations Thérapeutiques et Essais Précoces) bInserm Unit U981, Gustave Roussy Cancer Campus, Villejuif cFaculté du Kremlin Bicêtre, Université Paris Sud, France.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-oncology/2014/05000/Implemen
Web Search
http://dx.doi.org/10.1097/CCO.0000000000000077DOI Listing
May 2014

Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Clin Cancer Res 2014 Jan 15;20(1):246-52. Epub 2013 Nov 15.

Authors' Affiliations: Departments of Medical Oncology, Biostatistics and Epidemiology, Innovative Therapeutics and Early Drug Development, Radiology, and Radiotherapy; INSERM U981, University Paris Sud, Gustave Roussy, Villejuif, France; and Sage Bionetworks, Fred Hutchinson Cancer Research Center, Seattle, Washington.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947306PMC
January 2014

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

J Clin Oncol 2014 Jan 9;32(2):68-75. Epub 2013 Dec 9.

Leena Gandhi, Sara M. Tolaney, James M. Cleary, and Geoffrey I. Shapiro, Dana-Farber Cancer Institute; Eunice L. Kwak, Massachusetts General Hospital; Shuchi S. Pandya, Beth Israel Deaconess Medical Center, Boston; Anna Berkenblit and Mizue Krygowski, Aveo Pharmaceuticals; Revathi Ananthakrishnan and Kathleen W. Turnbull, Inventiv Health, Cambridge, MA; Rastislav Bahleda, Antoine Hollebecque, and Jean-Charles Soria, Insitut Gussav Roussy, Villejuif, France; Richat Abbas and Yali Liang, Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2012.47.2787
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.2787DOI Listing
January 2014

Targeted therapy-induced radiation recall.

Eur J Cancer 2013 May 8;49(7):1662-8. Epub 2013 Jan 8.

Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.12.009DOI Listing
May 2013

Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

Eur J Cancer 2013 May 16;49(7):1515-20. Epub 2013 Jan 16.

Service d'Innovation Thérapeutiques et Essais Précoces, Institut Gustave Roussy, Université Paris XI, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.12.012DOI Listing
May 2013

Peroxisome proliferator-activated receptors in HBV-related infection.

PPAR Res 2009 9;2009:145124. Epub 2009 Apr 9.

Institute National de la Santé et de la recherche Médicale INSERM, U795, 59037 Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2009/145124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2667936PMC
September 2012

[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors].

Bull Cancer 2012 Sep;99(9):865-74

Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/bdc.2012.1632DOI Listing
September 2012

Vascular disrupting agents: a delicate balance between efficacy and side effects.

Curr Opin Oncol 2012 May;24(3):305-15

Service d'Innovations Thérapeutiques Précoces, Département de Médecine, Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32835249deDOI Listing
May 2012

Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.

Invest New Drugs 2010 Aug 9;28(4):529-30. Epub 2009 May 9.

Département d'Oncologie Médicale, Centre Oscar Lambret, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-009-9262-4DOI Listing
August 2010

Development of a score that predicts survival among patients with bone metastasis revealing solid tumor.

Support Care Cancer 2008 Sep 14;16(9):1089-93. Epub 2008 May 14.

Département de Cancérologie Générale, Centre Oscar Lambret, 3 Rue F Combemale, Lille, France.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007%2Fs00520-008-04
Web Search
http://link.springer.com/10.1007/s00520-008-0455-8
Publisher Site
http://dx.doi.org/10.1007/s00520-008-0455-8DOI Listing
September 2008